Premium
New River Pharmaceuticals (MM) (NRPH)
NASDAQ
Hot Features
Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
NEW YORK, April 18 /PRNewswire/ -- HealthShares(TM) Inc., an investment company with a series of 20 underlying fund portfolios, today announced it has been informed by Standard & Poor's, the...
RADFORD, Va., April 3 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (NASDAQ:NRPH) today announced that, in connection with its previously disclosed pending acquisition by Shire plc...
RADFORD, Va., March 19 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (NASDAQ:NRPH) today announced that the waiting period under the Hart- Scott-Rodino Antitrust Improvements Act of...
RADFORD, Va., March 13 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (NASDAQ:NRPH) today announced its financial results for the year ended December 31, 2006. New River recognized a...
BASINGSTOKE, England, PHILADELPHIA, Pennsylvania and Radford, VIRGINIA, February 23 /PRNewswire-FirstCall/ -- Shire plc (LSE:SHPLSE:NASDAQ:LSE:SHPGYLSE: TSX:LSE:SHQ) and its collaborative...
RADFORD, Va., Feb. 20 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (NASDAQ:NRPH) announced today that it has signed a definitive agreement with Shire plc...
RADFORD, Va., Feb. 5 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (NASDAQ:NRPH) announced today that it plans to present at the 2007 Merrill Lynch Global Pharmaceutical...
RADFORD, Va., Jan. 25 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (NASDAQ:NRPH) announced today that James P. Shaffer has been appointed the company's Vice President, Sales and...
Launch Expected Q2 2007 BASINGSTOKE, U.K., PHILADELPHIA and RADFORD, Va., Dec. 21 /PRNewswire-FirstCall/ -- New River Pharmaceuticals Inc. (NASDAQ:NRPH) and its collaborative partner Shire plc...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
